Studies that used common variants in PNPLA3, TM6SF2 and GCKR as instruments to investigate the relationship between NAFLD and coronary artery disease (CAD) have reported contrasting results. This evidence concerns the gene GCKR and metabolic dysfunction-associated steatotic liver disease.